Surmodics, Inc. , a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a definitive agreement to be acquired by GTCR,.
Surmodics will be acquired by GTCR for $43.00 per share, totaling $627 million. This 41.1% premium reflects Surmodics' advancements in surface modification for medical devices and IVD technologies.
Eden Prairie-based Surmodics' stock soared Wednesday following news of its impending sale that will take the medical device company private. Private equity firm GTCR, based in Chicago, will pay $627 million or $43 per share for Surmodics when the transaction closes in the second half of the year, pending shareholder and regulatory approval. Health care and technology make up a main sector of .